Murray, Christopher W.; Berdini, Valerio; Buck, Ildiko M.; Carr, Maria E.; Cleasby, Anne; Coyle, Joseph E.; Curry, Jayne E.; Day, James E. H.; Day, Phillip J.; Hearn, Keisha; Iqbal, Aman; Lee, Lydia Y. W.; Martins, Vanessa; Mortenson, Paul N.; Munck, Joanne M.; Page, Lee W.; Patel, Sahil; Roomans, Susan; Smith, Kirsten; Tamanini, Emiliano; Saxty, Gordon published the artcile< Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors>, HPLC of Formula: 13451-78-0, the main research area is DDR inhibitor antitumor oral; back to front kinase design; discoidin domain receptor; fragment-based drug design.
The DDR1 and DDR2 receptor tyrosine kinases are activated by extracellular collagen and have been implicated in a number of human diseases including cancer. We performed a fragment-based screen against DDR1 and identified fragments that bound either at the hinge or in the back pocket associated with the DFG-out conformation of the kinase. Modeling based on crystal structures of potent kinase inhibitors facilitated the “”back-to-front”” design of potent DDR1/2 inhibitors that incorporated one of the DFG-out fragments. Further optimization led to low nanomolar, orally bioavailable inhibitors that were selective for DDR1 and DDR2. The inhibitors were shown to potently inhibit DDR2 activity in cells but in contrast to unselective inhibitors such as dasatinib, they did not inhibit proliferation of mutant DDR2 lung SCC cell lines.
ACS Medicinal Chemistry Letterspublished new progress about Conformation. 13451-78-0 belongs to class benzoxazole, and the molecular formula is C7H4FNOS, HPLC of Formula: 13451-78-0.
Referemce:
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem